These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23561650)

  • 1. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer.
    Johnson S; Jackson W; Li D; Song Y; Foster C; Foster B; Zhou J; Vainshtein J; Feng F; Hamstra D
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):554-61. PubMed ID: 23561650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):59-66. PubMed ID: 17919840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.
    Foster CC; Jackson WC; Foster BC; Johnson SB; Feng FY; Hamstra DA
    Radiat Oncol; 2014 Nov; 9():245. PubMed ID: 25424123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
    Jackson WC; Johnson SB; Li D; Foster C; Foster B; Song Y; Schipper M; Shilkrut M; Sandler HM; Morgan TM; Palapattu GS; Hamstra DA; Feng FY
    Radiat Oncol; 2013 Jul; 8():170. PubMed ID: 23835115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer.
    Buyyounouski MK; Pickles T; Kestin LL; Allison R; Williams SG
    J Clin Oncol; 2012 May; 30(15):1857-63. PubMed ID: 22508816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
    Jackson WC; Suresh K; Tumati V; Dess RT; Soni PD; Zhao SG; Zumsteg ZS; Hannan R; Hollenbeck BK; George A; Kaffenberger SD; Salami SS; Hearn JWD; Morgan TM; Mehra R; Schipper M; Feng FY; Desai NB; Spratt DE
    Eur Urol Oncol; 2018 Sep; 1(4):276-282. PubMed ID: 31100248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy.
    Johnson S; Jackson W; Speers C; Feng F; Hamstra D
    Pract Radiat Oncol; 2014; 4(6):422-9. PubMed ID: 25407865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
    Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
    Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
    Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
    Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
    BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.